MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

CASI Pharmaceuticals Company Profile (NASDAQ:CASI)

Consensus Ratings for CASI Pharmaceuticals (NASDAQ:CASI) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (156.41% upside)

Analysts' Ratings History for CASI Pharmaceuticals (NASDAQ:CASI)
Show:
DateFirmActionRatingPrice TargetActions
3/29/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/12/2016        
5/13/2016Q1($0.05)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/28/2016Q415($0.03)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2015Q215($0.06)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.05)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2014Q413($0.05)$0.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3($0.05)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q2 2013($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2013Q1 2013($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2013Q4 2012($0.02)$1.93 million$0.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for CASI Pharmaceuticals (NASDAQ:CASI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for CASI Pharmaceuticals (NASDAQ:CASI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CASI Pharmaceuticals (NASDAQ:CASI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Byte Ltd SparkleMajor ShareholderBuy3,753,855$1.19$4,467,087.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016China Growth Fund Idg-Accel IIMajor ShareholderBuy972,708$2.40$2,334,499.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Cynthia W. HuCOOBuy16,800$0.72$12,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Ken RenCEOBuy15,000$0.73$10,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for CASI Pharmaceuticals (NASDAQ:CASI)
DateHeadline
06/27/16 03:47 PMCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities -
06/18/16 07:42 AMTop 10 Orange is the New Black moments
06/13/16 10:18 AMCASI: Company Announces Positive Phase II Data on ENMD-2076 in Patients with OCCC At ASCO -
06/12/16 10:29 PMCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 - [at noodls] - Antitumor Activity, Safety and Predictive Biomarker Results to be Presented ROCKVILLE, Md., June 1, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics ...
06/03/16 03:47 PMCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/01/16 06:13 AMCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Cle - [at noodls] - Antitumor Activity, Safety and Predictive Biomarker Results to be Presented ROCKVILLE, Md., June 1, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics ...
06/01/16 06:00 AMCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC) - [PR Newswire] - ROCKVILLE, Md., June 1, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...
05/29/16 06:30 PMAnalysts Set 1-Year Price Target Of $3.75 On CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock - RealistInvestor.com - Analysts Set 1-Year Price Target Of $3.75 On CASI Pharmaceuticals, Inc. (NASDAQ:CASI) StockRealistInvestor.comSell-side analysts reveal their outlook on CASI Pharmaceuticals, Inc. (NASDAQ:CASI) stock. As of 2016-05-28, the stock has ABR of 1. This methodology prompts shareholders to invest in stock if it has a rating of 1. The ABR was known considering the ...and more »
05/29/16 09:52 AMCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Impact Score At 0 - Investor Newswire - CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Impact Score At 0Investor NewswireAlpha One explored various online articles released on CASI Pharmaceuticals, Inc. (NASDAQ:CASI), and it set a daily sentiment score of 0.498 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...and more »
05/28/16 06:33 PMHold Calls Count For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) At 0 - Investor Newswire - Hold Calls Count For CASI Pharmaceuticals, Inc. (NASDAQ:CASI) At 0Investor NewswireBuy calls count on CASI Pharmaceuticals, Inc. (NASDAQ:CASI)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has a total of 2 Strong Buy recommendations and 0 Strong Sell ...and more »
05/24/16 10:37 AMCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased 16.67% After Market Selling - Wall Street Hints and News - Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased 16.67% After Market SellingWall Street Hints and NewsThe short interest to Casi Pharmaceuticals Incorporated's float is 0.25%. The stock increased 3.39% or $0.04 on May 23, hitting $1.22. About 28,700 shares traded hands or 5.83% up from the average. CASI Pharmaceuticals Inc (NASDAQ:CASI) has declined ...and more »
05/21/16 12:04 PMCASI PHARMACEUTICALS, INC. Financials -
05/20/16 10:28 AMInsiders Are Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Wall Street Hints and News - Insiders Are Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at CASI Pharmaceuticals, Inc. (NASDAQ:CASI) have increased their position in the stock by 43.58%. Insiders now own 21.20% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
05/13/16 06:54 PMCASI Pharmaceuticals Reports First Quarter 2016 Financial Results - PR Newswire (press release) - CASI Pharmaceuticals Reports First Quarter 2016 Financial ResultsPR Newswire (press release)ROCKVILLE, Md., May 13, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported financial results for the three ...CASI Pharmaceuticals Reports Flat Q1 Loss, Revenues Drop (NASDAQ:CASI)Sonoran Weekly Reviewall 3 news articles »
05/13/16 06:54 PMCASI PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K) - Item 2.02 Results of Operations and Financial Condition. On May 13, 2016, CASI Pharmaceuticals, Inc. (the "Company") issued a press release reporting its financial results for the three month period ended March 31, 2016. The press release is furnished as ...
05/13/16 06:18 AMCASI Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - ROCKVILLE, Md., May 13, 2016 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported ...
05/12/16 07:02 PMCASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For ... - PR Newswire (press release) - CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For ...PR Newswire (press release)ROCKVILLE, Md., May 12, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces that China's Food and Drug ...CASI Pharmaceuticals Gets Approval in China To Conduct Phase 2 Clinical Trial to Treat Fibrolamellar Carcinoma ...Sonoran Weekly Reviewall 2 news articles »
05/12/16 06:27 AMCASI PHARMACEUTICALS RECEIVES APPROVAL FROM CFDA TO CONDUCT PHASE 2 CLINICAL TRIAL - [at noodls] - ROCKVILLE, Md., May 12, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces that China's ...
05/12/16 06:00 AMCASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) - [PR Newswire] - ROCKVILLE, Md., May 12, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...
05/09/16 06:47 PMCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorts Decreased by 20.33% After Short Covering - B.O.D.Y Confidential - Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorts Decreased by 20.33% After Short CoveringB.O.D.Y ConfidentialWellington Shields & Co. Llc holds 0.31% of its portfolio in CASI Pharmaceuticals Inc for 489,327 shares. Wellington Shields Capital Management Llc owns 465,359 shares or 0.08% of their US portfolio. Moreover, Moors & Cabot Inc. has 0.01% invested in ...and more »
04/20/16 07:15 PMBiotech Gainers: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), NeuroDerm Ltd. (NASDAQ:NDRM), Fortress Biotech, Inc ... - KC Register - Biotech Gainers: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), NeuroDerm Ltd. (NASDAQ:NDRM), Fortress Biotech, Inc ...KC RegisterCASI Pharmaceuticals, Inc. (NASDAQ:CASI) welcomes James E. Goldschmidt, Ph.D. to lead its business development team. Dr. Goldschmidt is responsible for developing new partnerships and brings to the Company more than 25 years of biotechnology and ...
04/18/16 07:57 PMStocks to Watch: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Gerdau S.A. (NYSE:GGB), JinkoSolar Holding Co., Ltd ... - KC Register - Stocks to Watch: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Gerdau S.A. (NYSE:GGB), JinkoSolar Holding Co., Ltd ...KC RegisterCASI Pharmaceuticals, Inc. (NASDAQ:CASI) stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued. In related news, major shareholder China Growth Fund Idg-Accel II acquired 972,708 shares of the firm's ...and more »
04/18/16 07:57 PMBRIEF-James Goldschmidt joins CASI Pharmaceuticals as vice president of business development - Reuters - BRIEF-James Goldschmidt joins CASI Pharmaceuticals as vice president of business developmentReutersApril 18 Casi Pharmaceuticals Inc. * James e. Goldschmidt, ph.d. Joins casi pharmaceuticals as vice president of business development Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780) ...
04/18/16 07:57 PMJames E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development - PR Newswire (press release) - James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business DevelopmentPR Newswire (press release)ROCKVILLE, Md., April 18, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, welcomes James E. Goldschmidt, Ph.D. to ...and more »
04/18/16 06:21 AMJames E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development - [at noodls] - ROCKVILLE, Md., April 18, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, welcomes James E. Goldschmidt, ...
04/15/16 07:18 PMCASI Pharmaceuticals, Inc. (NASDAQ:CASI)'s 52-Week Price Target At $3.00 - Investor Newswire - CASI Pharmaceuticals, Inc. (NASDAQ:CASI)'s 52-Week Price Target At $3.00Investor NewswireThomson Reuters completed its industry survey and following that it has given a 52-week price estimate of $3.00 to CASI Pharmaceuticals, Inc. (NASDAQ:CASI) stock. It is the average of the price estimates given by the brokerages during First Call survey.and more »
04/15/16 07:18 PMCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Reported Comprehensive Income Of $-0.0584 For Period Ended 2008--1 ... - Investor Newswire - CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Reported Comprehensive Income Of $-0.0584 For Period Ended 2008--1 ...Investor NewswireFor the annual period ended 2008–1-2-31, CASI Pharmaceuticals, Inc. (NASDAQ:CASI) posted comprehensive income of $-0.0584 millions. On quarterly basis, comprehensive income was $-0.0584 millions was the three-month period ended 2008–1-2-31.Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Decreased By 52.42%Business Standard Tribuneall 3 news articles »
04/11/16 07:04 PMCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased 22.79% After Market Selling - Clinton Financial - Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased 22.79% After Market SellingClinton FinancialThe short interest to Casi Pharmaceuticals Incorporated's float is 0.56%. The stock increased 18.02% or $0.2 on April 11, hitting $1.31. About 61,231 shares traded hands or 64.82% up from the average. CASI Pharmaceuticals Inc (NASDAQ:CASI) has ...and more »
04/04/16 07:20 PMRevenue Update on CASI Pharmaceuticals Inc(NASDAQ:CASI) - Street Edition - Revenue Update on CASI Pharmaceuticals Inc(NASDAQ:CASI)Street EditionCASI Pharmaceuticals Inc (CASI) shares turned negative on Wednesdays trading session with the shares closing down -0.1 points or -8.33% at a volume of 39,182. The pessimistic mood was evident in the company shares which never went considerably ...
04/01/16 06:59 PMCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Sellers Increased By 22.79% Their Shorts - Business Standard Tribune - Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Sellers Increased By 22.79% Their ShortsBusiness Standard TribuneThe short interest to Casi Pharmaceuticals Incorporated's float is 0.56%. The stock increased 1.89% or $0.02 on April 1, hitting $1.08. About 13,589 shares traded hands. CASI Pharmaceuticals Inc (NASDAQ:CASI) has declined 27.89% since August 25, 2015 ...
03/30/16 06:54 PMCASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results - PR Newswire (press release) - Financial Market NewsCASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial ResultsPR Newswire (press release)ROCKVILLE, Md., March 28, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the ...CASI Pharmaceuticals Inc (CASI) Given "Buy" Rating at HC WainwrightFinancial Market NewsCASI Pharmaceuticals Inc (CASI) Announces Earnings Results, Misses Estimates By $0.02 EPSSouth Florida Hedge Fund ManagersCASI Pharmaceuticals Inc (CASI) Issues Earnings Results, Misses Estimates By $0.02 EPSThe Vista VoiceWall Street 24 -Business Standard Tribuneall 11 news articles »
03/30/16 10:51 AMCASI Pharmaceuticals, Inc. :CASI-US: Earnings Analysis: 2015 By the Numbers -
03/30/16 10:01 AMMaking Moves: Gevo (NASDAQ:GEVO), CASI Pharmaceuticals (NASDAQ:CASI), Yahoo! Inc. (NASDAQ:YHOO), Itau ... - Property Mentor - Making Moves: Gevo (NASDAQ:GEVO), CASI Pharmaceuticals (NASDAQ:CASI), Yahoo! Inc. (NASDAQ:YHOO), Itau ...Property MentorAtlas Resource Partners, L.P. (NYSE:ARP) shares fell -1.43% in last trading session and ended the day at $0.68. ARP Gross Margin is 65.50% and its has a return on assets of -34.90%. Atlas Resource Partners, L.P. (NYSE:ARP) quarterly performance is ...and more »
03/30/16 10:01 AMWhy Need to Watch: CASI Pharmaceuticals, (NASDAQ:CASI), CPI Aerostructures (NYSEMKT:CVU), SunTrust Banks ... - KC Register - Why Need to Watch: CASI Pharmaceuticals, (NASDAQ:CASI), CPI Aerostructures (NYSEMKT:CVU), SunTrust Banks ...KC RegisterCASI Pharmaceuticals, Inc. (NASDAQ:CASI) reported financial results for the three and 12 months ended December 31, 2015. The Company reported a net loss of ($1.7 million), or ($0.05) per share, for the three months ended December 31, 2015.and more »
03/29/16 11:30 AMH.C. Wainwright Maintains a Buy Rating on CASI Pharmaceuticals - Analyst Ratings - H.C. Wainwright Maintains a Buy Rating on CASI PharmaceuticalsAnalyst RatingsIn a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on CASI Pharmaceuticals (NASDAQ: CASI). The company's shares closed yesterday at $1.19. CASI Pharmaceuticals has an analyst consensus of Hold.
03/28/16 11:59 AMNews Activity: CASI Pharmaceuticals (NASDAQ:CASI), Sumitomo Mitsui Financial Group (NYSE:SMFG), Invuity ... - Property Mentor - News Activity: CASI Pharmaceuticals (NASDAQ:CASI), Sumitomo Mitsui Financial Group (NYSE:SMFG), Invuity ...Property MentorBristow Group, Inc. (NYSE:BRS) shares increased 0.46% in last trading session and ended the day at $17.40. BRS Gross Margin is 26.30% and its has a return on assets of -1.00%. Bristow Group, Inc. (NYSE:BRS) quarterly performance is -30.24%.
03/28/16 11:59 AMCASI PHARMACEUTICALS : Results of Operations and Financial Condition (form 8-K) - Item 2.02 Results of Operations and Financial Condition. On March 28, 2016, CASI Pharmaceuticals, Inc. (the "Company") issued a press release reporting its financial results for the three month period and fiscal year ending December 31, 2015. The press ...
03/28/16 06:29 AMCASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results - [at noodls] - ROCKVILLE, Md., March 28, 2016 - CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial ...
03/24/16 11:14 AMAnalysis and CASI Pharmaceuticals Inc (CASI) Earnings Review - Clinton Financial - Analysis and CASI Pharmaceuticals Inc (CASI) Earnings ReviewClinton FinancialWall Street await CASI Pharmaceuticals Inc (NASDAQ:CASI) to release earnings on March, 25. Analysts forecast EPS of $-0.05, exactly $0.00 or 0.00% from 2014's $-0.05 EPS. After releasing $-0.05 EPS for the previous quarter, CASI Pharmaceuticals Inc's ...and more »
03/23/16 06:51 PMAnalysis and CASI Pharmaceuticals Inc (CASI) Earnings Review - OctaFinance.com - Analysis and CASI Pharmaceuticals Inc (CASI) Earnings ReviewOctaFinance.comAnalysts await CASI Pharmaceuticals Inc (NASDAQ:CASI) to reports earnings on March, 25. They expect $-0.05 EPS, 0.00 % or $0.00 from last year's $-0.05 per share. After $-0.05 actual EPS reported by CASI Pharmaceuticals Inc for the previous quarter, ...
03/22/16 06:37 PMCasi Pharmaceuticals Incorporated (NASDAQ:CASI) Sellers Increased By 1.6% Their Shorts - Stock Caller - Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Sellers Increased By 1.6% Their ShortsStock CallerThe short interest to Casi Pharmaceuticals Incorporated's float is 0.46%. The stock increased 0.69% or $0.01 on March 22, hitting $1.45. About 21,892 shares traded hands. CASI Pharmaceuticals Inc (NASDAQ:CASI) has declined 6.54% since August 14, ...
03/22/16 11:51 AMCasi Pharmaceuticals, Inc Has Another Bullish Trade, Zhejiang Kanglaite Group Co Bought Stake! - RiversideGazette.com - Casi Pharmaceuticals, Inc Has Another Bullish Trade, Zhejiang Kanglaite Group Co Bought Stake!RiversideGazette.comZhejiang Kanglaite Group Co filed with the SEC SC 13G form for Casi Pharmaceuticals, Inc. The form can be accessed here: 000114420416089202. As reported in Zhejiang Kanglaite Group Co's form, the filler as of late owns 5.03% or 2,057,613 shares of the ...
03/21/16 12:13 AM5 Top NASDAQ Biotech Stocks: GW Pharmaceuticals Spikes on Positive Results - The company closed at $72.72. Looking to commercialize therapeutics that address cancer and other unmet medical needs for the global market, with a primary focus on China, CASI Pharmaceuticals gained 68.59 percent last week. The company has posted no ...
02/24/16 10:27 AMCasi Pharmaceuticals, Inc. Company Profile - EntreMed wants to get in between cancer and the blood vessels that feed it. The biotech pharmaceutical company develops drugs that inhibit angiogenesis, or the growth of new blood vessels. Its lead candidate, ENMD-2076, inhibits aurora kinases which ...
02/13/16 09:13 AMNew report shares details about the metastatic breast cancer H2 2015 pipeline review research - Ltd., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, BIOCAD, Biocon Limited, Bionovis SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Campus Technologies Freiburg GmbH, CASI Pharmaceuticals Inc., Celgene Corporation, Celldex Therapeutics ...
02/10/16 02:17 PMCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -
02/06/16 04:09 PMCASI Pharmaceuticals, Inc. - CASI Pharmaceuticals, Inc., a biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in North America and China. The company s lead drug candidate is ENMD-2076, an Aurora A and ...
01/31/16 08:45 AMCASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma - ROCKVILLE, Md., Dec. 17, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs ...
01/22/16 09:51 AMCharles Schwab Corp (SCHW) and Two Low-Priced Stocks Witness Robust Insider Buying -
01/19/16 03:36 PMCASI Pharmaceuticals receives $10.3 million in strategic financing - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced ...
About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. Its product pipeline includes ENMD-2076, ZEVALIN, MARQIBO, CE Melphalan and 2ME2 (2-methoxyestradial). Its lead internal drug candidate is ENMD-2076 is a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ZEVALIN is indicated for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma. MARQIBO is indicated for the treatment of Philadelphia chromosome-negative acute lymphoblastic leukemia. Captisol Enabled melphalan is being investigated and is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. 2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties under reformulation development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CASI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.17
  • 50 Day Moving Average: $1.23
  • 200 Day Moving Average: $1.11
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $47.69M
  • Current Quarter EPS Consensus Estimate: $-0.16 EPS
Additional Links:
CASI Pharmaceuticals (NASDAQ:CASI) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha